Early use of donepezil against psychosis and cognitive decline in Parkinson’s disease: a randomised controlled trial for 2 years
Open Access
- 3 August 2018
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 89 (12) , 1332-1340
Abstract
Objectives Brain acetylcholine is decreased even in patients with cognitively preserved Parkinson’s disease (PD). We investigated whether early and long-term use of donepezil prevents psychosis in non-demented PD patients. Methods A double-blinded, placebo-controlled trial was conducted. A total of 145 non-demented PD patients were randomly assigned to receive 5 mg/day donepezil (n=72) or placebo (n=73) for 96 weeks. Medications for PD were not restricted, but antipsychotic drugs were not permitted throughout the study. The primary outcome measure was survival time to psychosis that was predefined by Parkinson’s Psychosis Questionnaire (PPQ) B score ≥2 or C score ≥2. Secondary outcome measures included psychosis developing within 48 weeks, total PPQ score, Mini-Mental State Examination (MMSE), Wechsler Memory Scale (WMS) and subgroup analysis by apolipoprotein ε4 genotyping. Results Kaplan-Meier curves for psychosis development were very similar between the two groups, and the Cox proportional hazard model revealed an adjusted HR of 0.87 (95%CI 0.48 to 1.60). The changes in MMSE and WMS-1 (auditory memory) were significantly better with donepezil than in placebo. In the subgroup analysis, donepezil provided an HR of 0.31 (0.11–0.86) against psychosis in 48 weeks for apolipoprotein ε4 non-carriers. Conclusions Although donepezil provided beneficial effects on PPQ, MMSE and auditory WMS score changes in 2 years, it had no prophylactic effect on development of psychosis in PD. Apolipoprotein ε4 may suppress the antipsychotic effect of donepezil. Trial registration number UMIN000005403.Keywords
Funding Information
- National Hospital Organization, Tokyo, Japan
This publication has 46 references indexed in Scilit:
- Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort studyBMC Neurology, 2013
- Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP)BMJ Open, 2013
- Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s diseaseReviews in the Neurosciences, 2013
- Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety studyMovement Disorders, 2012
- Prevalence of Psychotic Symptoms in a Community-Based Parkinson Disease SampleThe American Journal of Geriatric Psychiatry, 2012
- Disease‐related and genetic correlates of psychotic symptoms in Parkinson's diseaseMovement Disorders, 2011
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease PsychosisNeuropsychopharmacology, 2009
- Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's diseaseBrain, 2009
- Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's diseaseInternational Journal of Geriatric Psychiatry, 2004